Skip to Main Content

In the latest bid to address high prescription drug costs, a nonprofit plans to sell a cheaper generic version of an expensive cancer medicine in the U.S.

Civica Rx, which was formed four years ago, is working with a generic manufacturer, Hikma Pharmaceuticals, to supply pharmacies with the abiraterone prostate cancer treatment for $160 for a month’s supply. And the nonprofit is suggesting pharmacies sell the medicine to consumers for $171, which is considerably less than what most consumers currently pay. The brand-name version is Zytiga.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment